匈牙利吉瑞制药公司宣布,已与澳大利亚Acrux公司就其2013年签署的、关于透皮雌二醇喷雾Lenzetto在澳大利亚市场的许可协议达成延期协议。双方同意延长该许可协议的有效期,继续在澳大利亚市场推广和销售Lenzetto产品。
匈牙利吉瑞制药公司宣布,已与澳大利亚Acrux公司就其2013年签署的、关于透皮雌二醇喷雾Lenzetto在澳大利亚市场的许可协议达成延期协议。双方同意延长该许可协议的有效期,继续在澳大利亚市场推广和销售Lenzetto产品。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.